mynth
← DATABASE
12/2020

HIPPOCRATES (LAF - LA FARMACIA) acquired by ANTIN INFRASTRUCTURE

ITALY Health Providers / Outpatient Care / Pharmacy EV 500M - 1.5b EUR

Context

Antin Infrastructure Partners acquired a majority stake (approximately 80%) in Hippocrates Holding. The co-founders reinvested to retain the remaining 20% and maintained their roles as co-CEOs. The original investors (including DVR Capital and Italian family offices such as the Notarbartolo and Marzotto families) sold their shares in this transaction. The transaction was intended to provide the capital needed to accelerate the consolidation strategy in the highly fragmented Italian pharmacy market.

HIPPOCRATES (LAF - LA FARMACIA), which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Hippocrates Holding is the leading independent pharmacy network in Italy. Founded in 2018 by Davide Tavaniello and Rodolfo Guarino, the group operates 615 pharmacies under the proprietary brand "LaF" (La Farmacia). It aggregates independent pharmacies into a centrally managed corporate network, offering Corporate efficiencies and standardized services.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2020
LOGIN
LOGIN
LOGIN
2019
LOGIN
LOGIN
LOGIN

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
DateAcquirerTargetCountrySectorDeal Context
03/2021TRITON PARTNERSBERGMAN CLINICSNETHERLANDSHealth Providers

Triton completed an investment in Bergman Clinics alongside existing shareholders NPM Capital and the Malenstein family, who both retained minority positions in the business. The transaction followed a competitive sale process mandated to JP Morgan and Axeco Corporate Finance, which attracted interest from TowerBrook Capital Partners, Cinven, Bain Capital, and BC Partners before Triton emerged as the winning bidder. The process had originally been launched in early 2020 but was put on hold due to the COVID-19 pandemic before being revived in September 2020. Triton's investment is intended to support Bergman Clinics' continued geographic expansion, as well as investment in technological innovation, digitisation, and staff training.

02/2021SILVER LAKE / NESTLEIVC EVIDENSIAUNITED KINGDOMHealth Providers

Silver Lake and Nestle led a EUR3.5 billion capital investment in IVC Evidensia, significantly increasing the group's valuation. The deal allowed EQT VII to partially exit its position, while EQT IX reinvested to remain the majority shareholder. The transaction served as a private alternative to a previously considered IPO. Silver Lake's entry is designed to accelerate the group's digital transformation, while Nestle's increased stake facilitates deep collaboration between veterinary clinical care and nutritional science. This "pet-tech" and "pet-health" convergence aims to create a data-driven ecosystem for pet owners, enhancing diagnostic accuracy and tailored health solutions across IVC's pan-European network.

12/2020FRESENIUSEUGIN GROUPSPAINHealth Providers

Fresenius Helios, the hospital and healthcare services division of Fresenius SE & Co. KGaA, acquired Eugin Group from NMC Health, a UAE-based listed healthcare group, through a dual acquisition structure targeting both the global ex-US operations (via Luarmia S.L.) and the US operations (via NMC Eugin US Corporation, holding 70% of Boston IVF). The remaining 30% of Boston IVF continues to be held by its senior physicians. The transaction establishes Fresenius Helios as a leading international fertility services provider and creates a new dedicated business and reporting unit — alongside Helios Germany and Helios Spain — with a mandate to pursue further buy-and-build expansion.

12/2020MEDIAN KLINIKENPRIORY GROUPUNITED KINGDOMHealth Providers

MEDIAN Kliniken, a Waterland Private Equity portfolio company, agreed to acquire 100% of Priory Group from US-based Acadia Healthcare. Following closing, Waterland intends to combine Priory with MEDIAN to create a leading European rehabilitation and mental health services provider, operating 570 facilities and treating approximately 260,000 patients annually across the UK and Germany. The strategic rationale centres on geographic diversification into the UK market, cross-fertilisation of clinical expertise (particularly expanding Priory's rehabilitation services in neurology and post-acute care), and the transfer of MEDIAN's digital innovation capabilities to Priory's platform. The transaction represents the 22nd bolt-on acquisition in MEDIAN's buy-and-build strategy since Waterland's initial investment in 2011.

11/2020ERGON CAPITAL PARTNERSVIDACURAGERMANYHealth Providers

Ergon Capital, acting through its acquisition vehicle SCUR-Alpha 1227 GmbH, acquired 100% of VidaCura's inpatient and ambulatory nursing care operations following clearance from the German Federal Cartel Office (Bundeskartellamt) on November 26, 2020. The transaction represents the largest single healthcare deal in Germany in 2020 by number of care places. The deal adds 3,421 care places across 37 nursing homes and assisted living facilities to Ergon Capital's German healthcare portfolio, complementing its existing investment in out-of-hospital intensive care operator opseo.

11/2020L CATTERTONALLIANCE ANIMAL HEALTHUNITED STATESHealth Providers

L Catterton acquired a majority stake in Alliance Animal Health at a valuation up to $800M. The deal reflects the high demand for recession-resistant veterinary services. Under LightBay Capital's ownership (since June 2019), Alliance grew its EBITDA fivefold to reach $39M (pro forma adjusted). The entry of L Catterton aims to accelerate the company's buy-and-build strategy in a highly fragmented market, benefiting from the increased pet ownership trend and the essential nature of veterinary care.

11/2020DWS GROUPMEDIPASSITALYHealth Providers

DWS Alternatives Global Limited has acquired 100% of Medipass srl, a leading provider of cancer care and advanced diagnostic imaging services in Italy and the United Kingdom.

11/2020MEDICA GROUPGLOBAL DIAGNOSTICSIRELANDHealth Providers

Global Diagnostics Ireland, which operates around 50 clinical centers across Ireland, has been acquired by Medica Group. For Medica, this acquisition represents a diversification of its customer base and geographic activities, as well as entry into a new market: ophthalmology and retinopathy screening.

11/2020ARDIANINOVIE GROUPFRANCEHealth Providers

Ardian led a consortium to acquire a minority stake (approx. 40% of financial rights) in Inovie. Due to French law (SEL), clinical biologists must retain the majority of voting rights and capital. The deal was designed to solve a "generational transition" problem, allowing ~130 older biologists to retire and cash out their shares while enabling younger biologists to buy in at normalized salary levels. The capital injection was earmarked for massive consolidation (Buy-and-Build) in the fragmented French lab market and for scaling specialized diagnostics.

10/2020KKR / TETHYS INVEST / ARDIAN / CNP ASSURANCES / MERIEUX EQUITY PARTNERSELSANFRANCEHealth Providers

KKR led a leveraged buyout of Elsan, becoming the majority shareholder with 43% of the capital. CVC Capital Partners, an existing shareholder, reinvested and retained a 22% stake. A French institutional investor pool holding 35% of the capital was assembled alongside KKR and CVC, comprising Téthys Invest (~15%), Ardian (~7%), AXA (~5%), CNP Assurances (via its infrastructure investment activity), and Mérieux Equity Partners. The French pool was deliberately structured to ensure strong domestic institutional backing given the strategic importance of private hospitalisation in France, heightened by the COVID-19 pandemic.

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 150M - 250M EUR

EBITDA range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HIPPOCRATES (LAF - LA FARMACIA) by ANTIN INFRASTRUCTURE are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: hippocrates (laf - la farmacia)

Acquirer: antin infrastructure